

Antibody Technology Companies 2010 - A systematic guide through the landscape of antibody technologies and their providers

<https://marketpublishers.com/r/AAD6C5CD494EN.html>

Date: November 2010

Pages: 283

Price: US\$ 1,394.00 (Single User License)

ID: AAD6C5CD494EN

Abstracts

The report “Antibody Technology Companies 2010 – A systematic guide through the landscape of antibody technologies and their providers” provides a description and assessment of antibody technologies and their corporate providers as of November 2010. The report describes and analyzes the market size of therapeutic monoclonal antibodies and Fc-fusion proteins in 2009. Characteristics of approved antibody-based products regarding identification, construction and manufacturing are evaluated as a basis for relevant antibody technologies in 2010. Systematic profiles of 96 companies engaged in antibody technologies serve as the basis to present in a structured manner four clusters of platform technologies (generation, optimization, novel constructs, expression/manufacturing). The report serves as a systematic guide through the landscape of companies with antibody technologies for those in search of service providers or partners for collaboration or licensing.

Background

As of October 2010, 34 original therapeutic monoclonal antibodies and Fc-fusion proteins are marketed with 2009 sales exceeding US\$ 45.4 bln. Thus, antibodies as a therapeutic modality and technology have matured and availability of new technologies as well as patent expirations offer a multitude of new options when designing an antibody-based product. While the established providers of transgenic mice have been acquired by Big Pharma/Biotech, a plethora of new antibody technologies appeared. Although this landscape of technologies for antibody lead generation and optimization, creation of combinatorial biologics and for expression/manufacturing offers an unprecedented range of possibilities, the selection of the most robust and adequate technologies fitting fitting to the product target profile has become more difficult than

ever.

Scope of the report

Antibody market 2009

Technology analysis of 37 approved therapeutic antibody-based products

Profiles of 96 antibody technology companies

Antibody technology assessment

Antibody pipelines of technology companies

Overview of landscape of antibody technologies

Guide to identify suitable technologies and providers

Index

Overview

Market Size of Therapeutic Monoclonal Antibodies and Fc-Fusion Proteins in 2009

Characteristics of Approved Therapeutic Monoclonal Antibodies and Fc-Fusion Proteins

Platform Technologies for the Generation of Novel Therapeutic Antibody-based Products

Platform Technologies for the Optimization of Novel Therapeutic Antibody-based Products

Platform Technologies for Products beyond Monoclonal Antibodies

Platform Technologies for the Expression and Manufacturing of Novel Therapeutic Antibodies and Antibody-based Products

Contents

1 OVERVIEW

2 MARKET SIZE OF THERAPEUTIC MONOCLONAL ANTIBODIES AND FC-FUSION PROTEINS IN 2009

3 CHARACTERISTICS OF APPROVED THERAPEUTIC MONOCLONAL ANTIBODIES AND FC-FUSION PROTEINS¹⁶

4 PLATFORM TECHNOLOGIES FOR THE GENERATION OF NOVEL THERAPEUTIC ANTIBODYBASED PRODUCTS

- 4.1 In vivo generation of antibodies
- 4.2 In vitro generation of antibodies
- 4.3 Outlook

5 PLATFORM TECHNOLOGIES FOR THE OPTIMIZATION OF NOVEL THERAPEUTIC ANTIBODYBASED PRODUCTS

- 5.1 Use of natural immunoglobulin variants
- 5.2 Mutated immunoglobulins
- 5.3 Glyco-engineering
- 5.4 Improvement of pharmaceutical quality
- 5.5 Outlook

6 PLATFORM TECHNOLOGIES FOR PRODUCTS BEYOND MONOCLONAL ANTIBODIES

- 6.1 Oligoclonal antibodies
- 6.2 Engineering of novel antibody-based products
- 6.3 Outlook

7 PLATFORM TECHNOLOGIES FOR THE EXPRESSION AND MANUFACTURING OF NOVEL THERAPEUTIC ANTIBODIES AND ANTIBODY-BASED PRODUCTS

- 7.1 Mammalian cells
- 7.2 Other eukaryotic systems
- 7.3 Yeast expression

7.4 Bacterial expression

7.5 Outlook

Tables

TABLES

Table 1: Sales of Therapeutic Monoclonal Antibodies and Fc-Fusion Proteins in 2009 with Source of Information

Table 2: Sales of Therapeutic Monoclonal Antibodies and Fc-Fusion Proteins in 2009 by Product

Table 3: Sales of Therapeutic Monoclonal Antibodies and Fc-Fusion Proteins in 2009 by Therapeutic Area

Table 4: Sales of Therapeutic Monoclonal Antibodies and Fc-Fusion Proteins in 2009 by Target

Table 5: Characteristics of Approved Therapeutic Monoclonal Antibodies and Fc-Fusion Proteins

Table 6: Generation of Monoclonal Antibodies in vivo

Table 7: Generation of Monoclonal Antibodies by B-cell Isolation

Table 8: Generation of Monoclonal Antibodies in vitro

Table 9: Generation of Monoclonal Antibodies in Cells in vitro

Table 10: Modification of Monoclonal Antibodies for Function – Protein and Glyco-Engineering

Table 11: Improvement of Pharmaceutical Quality of Antibodies

Table 12: Oligo- and Polyclonal Antibodies

Table 13: Novel Antibody-derived Formats by Protein Engineering

Table 14: Chemical and Protein Conjugates of Antibodies

Table 15: Automation of Antibody Lead Identification and Optimization

Table 16: Antibody: Druggability, Cross-Reactivity, Target Discovery and Others

Table 17: Expression and Manufacturing of Monoclonal Antibodies

Figures

FIGURES

Figure 1 Evolution of the Productivity of Mammalian Cell Culture

Figure 2 Calculation of Cost Structure for a Mammalian Cell Culture Process of a Recombinant Monoclonal Antibody – part I

Figure 3 Calculation of Cost Structure for a Mammalian Cell Culture Process of a Recombinant Monoclonal Antibody – part II

ADDENDUM

COMPANY PROFILES

4-Antibody

Abcheck

Abeome

Ablexis

Ablynx

AdAlta

Adimab

Affimed Therapeutics

Affitech

Alder Biopharmaceuticals

Alligator Biosciences

Ambrx

AnaptysBio

Antitope

arGEN-X

Armagen Technologies

Avanir Pharmaceuticals

Avipep

BioAtla

BioInvent

Biolex Therapeutics

Biosite

Biotecnol

Bristol-Myers Squibb (Medarex)

Calmune

Cephalon (Arana Therapeutics)
Chiome Bioscience
Crescendo Biologics
CytomX
Cytos
Discerna
Dyax
Elusys Therapeutics
Emergent Biosolutions (Trubion Pharmaceuticals)
Epitomics & Apexigen
Epivax
Esbatech & Delenex
Evec
ExcellImmune
f-star
Ganymed Pharmaceuticals
Genexine
Genmab
GlaxoSmithKline (Domantis)
Glycotope
GTC Biotherapeutics
Immunocellular Therapeutics
Immunogen
InNexus
InterVexion Therapeutics
Johnson & Johnson (Crucell)
Kalo Bios
Kenta Biotech
Kolltan
Kyowa Hakko Kirin (BioWa)
Lonza
MabCure
Macrogenics
MAT Biopharma
Merck & Co (GlycoFi)
Merrimack Pharmaceuticals
Merus
Micromet
Millegen

Morphosys
Morphotek
MSM Protein Technologies
Nascent Biologics
Neurimmune
North Coast Biologics
Open Monoclonal Technology (OMT)
OriGene Technologies
Oxford Biotherapeutics
Patrys
Pepscan Therapeutics
Pfizer (CovX)
Philogen
Planet Biotechnology
Regeneron
Sea Lane Biotechnologies
Seattle Genetics
Sloning Biotechnology
Sorrento Therapeutics
Symphogen
Synageva
Syntarga
Theraclone
Trellis
TRION Pharma
Vaccinex
Vivalis
Viventia Biotechnologies
XBiotech
Xencor
XOMA
Xori

I would like to order

Product name: Antibody Technology Companies 2010 - A systematic guide through the landscape of antibody technologies and their providers

Product link: <https://marketpublishers.com/r/AAD6C5CD494EN.html>

Price: US\$ 1,394.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AAD6C5CD494EN.html>